United Therapeutics (NSDQ:UTHR) today signed a deal to acquire competitor SteadyMed (NSDQ:STDY) for $4.46 per share in cash at closing and $2.63 per share in cash if the combined company can win approval for SteadyMed’s Trevyent drug-device combination therapy.
The merger, valued at $216 million, combines two companies that were in court as recently as last November, fighting over patents covering treprostinil, the active ingredient in both companies’ lead products.
Get the full story at our sister site, Drug Delivery Business News.
The post United Therapeutics puts $216m on the table to buy rival SteadyMed appeared first on MassDevice.
from MassDevice https://ift.tt/2FsNcLp
Cap comentari:
Publica un comentari a l'entrada